These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 30519317)

  • 1. Prognostic Influence of the Time Interval between Surgery and Chemotherapy in Epithelial Ovarian Cancer.
    Liu XD; Liu Y; Gong TT; Guo JY; Wang YN; Wang L; Wu QJ; Jiao YS
    J Cancer; 2018; 9(22):4172-4178. PubMed ID: 30519317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ABO Blood Type Has No Impact on Survival in Patients with Epithelial Ovarian Cancer.
    Wang L; Yang Z; Liu Y; Wang YN; Guo JY; Wu QJ; Gong TT
    J Cancer; 2018; 9(23):4334-4340. PubMed ID: 30519337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interval between debulking surgery and adjuvant chemotherapy is associated with overall survival in patients with advanced ovarian cancer.
    Timmermans M; van der Aa MA; Lalisang RI; Witteveen PO; Van de Vijver KK; Kruitwagen RF; Sonke GS
    Gynecol Oncol; 2018 Sep; 150(3):446-450. PubMed ID: 30001834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of preoperative hyponatremia in patients with epithelial ovarian cancer.
    Guo JY; Gong TT; Yang Z; Liu Y; Wang L; Wang YN; Wu QJ
    J Cancer; 2019; 10(4):836-842. PubMed ID: 30854089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary debulking surgery versus primary neoadjuvant chemotherapy for high grade advanced stage ovarian cancer: comparison of survivals.
    Kobal B; Noventa M; Cvjeticanin B; Barbic M; Meglic L; Herzog M; Bordi G; Vitagliano A; Saccardi C; Skof E
    Radiol Oncol; 2018 Sep; 52(3):307-319. PubMed ID: 30210049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does Time-to-Chemotherapy after Primary Complete Macroscopic Cytoreductive Surgery Influence Prognosis for Patients with Epithelial Ovarian Cancer? A Study of the FRANCOGYN Group.
    Rocher G; Gaillard T; Uzan C; Collinet P; Bolze PA; Ballester M; Bendifallah S; Ouldamer L; Touboul C; Huchon C; Lavoue V; Dabi Y; Akladios C; Coutant C; Raimond E; Bricou A; Canlorbe G; Azaïs H
    J Clin Med; 2021 Mar; 10(5):. PubMed ID: 33806443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: analysis of prospective randomised phase III trials.
    Mahner S; Eulenburg C; Staehle A; Wegscheider K; Reuss A; Pujade-Lauraine E; Harter P; Ray-Coquard I; Pfisterer J; du Bois A
    Eur J Cancer; 2013 Jan; 49(1):142-9. PubMed ID: 22921185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of the time interval between primary or interval surgery and adjuvant chemotherapy in ovarian cancer patients.
    Farolfi A; Petracci E; Gurioli G; Tedaldi G; Casanova C; Arcangeli V; Amadori A; Rosati M; Stefanetti M; Burgio SL; Cursano MC; Lolli C; Zampiga V; Cangini I; Schepisi G; De Giorgi U
    Front Oncol; 2023; 13():1221096. PubMed ID: 37664032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Body weight changes in patients undergoing chemotherapy for ovarian cancer influence progression-free and overall survival.
    Mardas M; Stelmach-Mardas M; Madry R
    Support Care Cancer; 2017 Mar; 25(3):795-800. PubMed ID: 27771784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival and prognostic factors in patients with recurrent low-grade epithelial ovarian cancer: An analysis of five prospective phase II/III trials of NOGGO metadata base.
    Canaz E; Grabowski JP; Richter R; Braicu EI; Chekerov R; Sehouli J
    Gynecol Oncol; 2019 Sep; 154(3):539-546. PubMed ID: 31230821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined score of pretreatment platelet count and CA125 level (PLT-CA125) stratified prognosis in patients with FIGO stage IV epithelial ovarian cancer.
    Chen JP; Huang QD; Wan T; Tu H; Gu HF; Cao JY; Liu JH
    J Ovarian Res; 2019 Jul; 12(1):72. PubMed ID: 31362750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential risk factors associated with prognosis of neoadjuvant chemotherapy followed by interval debulking surgery in stage IIIc-IV high-grade serous ovarian carcinoma patients.
    Zhang J; Liu N; Zhang A; Bao X
    J Obstet Gynaecol Res; 2018 Sep; 44(9):1808-1816. PubMed ID: 30019801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Polymorphisms of ERCC1 gene and outcomes in epithelial ovarian cancer patients with platinum-based chemotherapy].
    Qi BL; Li Y; Wang N; Zhou RM; Hu P; Kang S
    Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):847-52. PubMed ID: 24444563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histopathology predicts clinical outcome in advanced epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and debulking surgery.
    Muraji M; Sudo T; Iwasaki S; Ueno S; Wakahashi S; Yamaguchi S; Fujiwara K; Nishimura R
    Gynecol Oncol; 2013 Dec; 131(3):531-4. PubMed ID: 24096109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prognostic significance of preoperative leukocytosis in epithelial ovarian carcinoma: a retrospective cohort study.
    So KA; Hong JH; Jin HM; Kim JW; Song JY; Lee JK; Lee NW
    Gynecol Oncol; 2014 Mar; 132(3):551-5. PubMed ID: 24440470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Re-evaluation of interval debulking surgery in advanced epithelial ovarian cancer].
    Ma Y; Li Y; Cui H; Liang XD; Tang ZJ; Li XP; Zhao Y; Wei LH
    Zhonghua Fu Chan Ke Za Zhi; 2012 May; 47(5):355-60. PubMed ID: 22883524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytokine profiling of ascites at primary surgery identifies an interaction of tumor necrosis factor-α and interleukin-6 in predicting reduced progression-free survival in epithelial ovarian cancer.
    Kolomeyevskaya N; Eng KH; Khan AN; Grzankowski KS; Singel KL; Moysich K; Segal BH
    Gynecol Oncol; 2015 Aug; 138(2):352-7. PubMed ID: 26001328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Value and Implication for Chemotherapy Treatment of ABCB1 in Epithelial Ovarian Cancer: A Meta-Analysis.
    Sun S; Cai J; Yang Q; Zhu Y; Zhao S; Wang Z
    PLoS One; 2016; 11(11):e0166058. PubMed ID: 27812204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of primary intraperitoneal chemotherapy to consolidation intraperitoneal chemotherapy in optimally resected advanced ovarian cancer.
    Suidan RS; St Clair CM; Lee SJ; Barlin JN; Long Roche KC; Tanner EJ; Sonoda Y; Barakat RR; Zivanovic O; Chi DS
    Gynecol Oncol; 2014 Sep; 134(3):468-72. PubMed ID: 25042672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CA-125 Levels Are Predictive of Survival in Low-Grade Serous Ovarian Cancer-A Multicenter Analysis.
    Wohlmuth C; Djedovic V; Kjaer SK; Jensen A; Glasspool R; Roxburgh P; DeFazio A; Johnatty SE; Webb PM; Modugno F; Lambrechts D; Schildkraut JM; Berchuck A; Thomsen LCV; Bjorge L; Høgdall E; Høgdall CK; Goode EL; Winham SJ; Matsuo K; Karlan BY; Lester J; Goodman MT; Thompson PJ; Pejovic T; Riggan MJ; Lajkosz K; Tone A; May T
    Cancers (Basel); 2022 Apr; 14(8):. PubMed ID: 35454861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.